Pharmacology of the new target-specific oral anticoagulants

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 2, 2013, Pages 133-140

  Cabral, Katherine P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Apixaban; Dabigatran; Edoxaban; Oral anticoagulants; Pharmacodynamics; Pharmacokinetics; Pharmacology; Rivaroxaban; Target specific anticoagulants

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN ETEXILATE; DIGOXIN; EDOXABAN; GLYCOPROTEIN P INHIBITOR; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOPERAMIDE; NELFINAVIR; PHENOBARBITAL; PHENYTOIN; PYRROLE DERIVATIVE; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TACROLIMUS; TAMOXIFEN; THROMBIN INHIBITOR; UNINDEXED DRUG; VERAPAMIL; WARFARIN; XIMELAGATRAN; THROMBIN;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; DRUG DELIVERY SYSTEMS; FACTOR XA INHIBITORS; HUMANS; THROMBIN;

EID: 84881479575     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0929-5     Document Type: Article

References (52)

1. Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48:1-22
2. Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. NEJM 353(10):1028-1040
3. Bauer KA (2006) New anticoagulants: Anti IIa vs. Anti Xa - is one better? J Thromb Thrombolysis 21(1):67-72
4. Executive Steering Committee on behalf of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362:1691-1698
5. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293:690-698
6. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (2002) Structured-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45:1757-1766
7. Wienen W, Stassen JM, Priepke H et al (2007) Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rates. Thromb Haemost 5(6):1237-1242
8. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5):285-295
9. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, vanRyn J (2010) Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 30:1885-1889
10. Pradaxa prescribing information (2012) http://bidocs.boehringer- ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 9 Oct 2012
11. Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 361(12):1139-1151
12. Nutescu E, Chuatrisorn I, Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31:326-343
13. Stangier J, Stahle H, Rathgen K et al (2008) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran in healthy elderly subjects. Clin Pharmacokinet 47(1):47-59
14. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Rother W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386-399
15. Stangier J, Rathgen K, Stahl H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303
16. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259-268
17. Chang DN, Dager WE, Chin AI (2013) Removal of dabigatran by hemodialysis. Am J Kid Dis 61(3):487-489
18. Stanger J, Stahle H, Rathgen K et al (2008) The pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. doi: 10.1177/0091270008324179
19. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42(1):59-98
20. Yasuda K et al (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharm Exp Ther 303(1):323-332
21. Jungbauer L, Dobias C, Stollberger C, Weidinger F (2010) The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost 8(9):2069-2070
22. Walenga JM, Adiguzel C (2010) Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64(7):956-967
23. Alexander JH, Singh KP (2005) Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drug 5(5):279-290
24. Rai R, Sprengeler PA, Elrod KC, Young WB (2001) Perspectives on factor Xa inhibition. Curr Med Chem 8:101-119
25. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939: an oral, direct factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873-880
26. Perzborn E, Strassburger J, Wilmen A et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514-521
27. Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939: an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412-421
28. Kubitza D et al (2006) Effects of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in health subjects. J Clin Pharmcol 46(5):549-558
29. http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf#zoom=100. Accessed 9 Oct 2012
30. Weinz C, Radtke M, Schmeer K et al (2004) In vitro metabolism of BAY 59-7939: an oral, direct factor Xa inhibitor [abstract 195]. Drug Metab Rev 36(Suppl 1):98
31. Gulseth M, Michaud J, Nutescu EA (2008) Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 65:1520-1529
32. Kubitza D, Becka M, Mueck W et al (2006) The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban, an oral direct factor Xa inhibitor. Blood 108:905. Abstract
33. Kubitza D, Becka M, Mueck W et al (2007) The effect of age and gender on the pharmacology and safety of the oral, direct factor Xa inhibitor. J Thromb Haemost 5(Suppl 2):P-T-628. Abstract
34. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74-81
35. Squibb B-M (2012) Eliquis: summary of product characteristics. http://www.eliquis.com/pdf/ELIQUIS%20%C2%AE%20%28apixaban%29%20SmPC.pdf. Accessed 4 Oct 2012
36. Frost C, Yu Z, Moore K et al (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2):PT633. Abstract
37. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F (2012) Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2012.04369.x
38. Frost C, Yu Z, Shenker A et al (2008) Food does not affect the pharmacokinetics of apixaban, an oral, factor Xa inhibitor. Can J Clin Pharmacol 15:e469. Abstract
39. Wang L, Zhang D, Raghavan N et al (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studies. Drug Metab Dispos 38:448-458
40. Ufer M (2010) Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 103:572-585
41. Frost CE, Yu Z, Wang J et al (2009) Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 85(Suppl 1):S34. Abstract
42. Frost CE, Nepal S, Barrett YC et al (2009) Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Throm Haemost 7(Suppl 2):PP-MO-407. Abstract
43. Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
44. Frost C, Wang J, Nepal S et al (2007) Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. J Clin Pharmacol 49:1091-1130. Abstract
45. Furugohri T, Isobe K, Honda Y et al (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6(9):1542-1549
46. Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743-753
47. Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct factor Xa inhibitor. Drugs 71(12):1503-1526
48. Mendell J, Tachibana M, Shi M et al (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51(5):687-694
49. Masumoto H, Yoshigae Y, Watanabe K, Takakusa U, Okazaki O, Izumi T (2012) In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. http://www.aapsj.org/abstracts/AM-2010/W4308.pdf. Accessed 15 Oct 2012
50. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635-641
51. http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca-EN/ documents/humanhealth/product-monograph/Pradax-pm.pdf. Accessed 4 Apr 2013
52. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000829/WC500041059.pdf. Accessed 4 Apr 2013